Introduction
============

The patient package inserts (PPIs) are included by law in the packaging of drugs and contain information for the user. They are the most readily available form of written information on drugs for patients. The leaflet is meant to be clear and understandable to the general population. The PPIs should increase patient\'s awareness of medication-related issues, contribute to the safe and correct use of the medication, and help in the success of the treatment plan.[@B1],[@B2] In developing countries, the PPI is considered an important source of drug information for healthcare providers as well, because of a limited ability to access up to date drug information resources. Even though it is an important source of information, several studies from different countries have shown a need to improve the content and readability of the PPI.[@B1],[@B2],[@B3],[@B4],[@B5],[@B6],[@B7],[@B8] Despite efforts to improve the readability and comprehensibility, by both the drug regulatory authorities and the manufactures, package inserts are still criticized.[@B1],[@B3],[@B4],[@B5] This is mainly due to the extensive volume of incomprehensible text and the small font size used, which people find distressing.[@B5],[@B9]

Risks for medication misuse highlight the importance of reviewing package inserts and labels prior to taking medications. Reading package labels is a key source of information about medications for many consumers especially in developing countries where self-medication is well documented and access to clinicians and pharmacists might be limited, so incomplete or inaccurate information in PPIs might increase medication errors and drug-related problems.[@B10] Globally there is considerable variation in the information included in the package inserts or leaflets, as well as the primary users they are directed toward. The design and the amount of information in the PPIs are usually regulated by the legislative health authorities. The medications in community pharmacies in Palestine are almost exclusively available by branded unit-of-use, with a product insert inside every package. This informative insert is directed toward the users and must give full and comprehensible information about the drug. The Palestinian Ministry of Health (MoH) recommends that all marketed medications be supplied with a PPI that is written in both Arabic and English, but there are no regulations regarding the quality or the quantity of the information, design and wording of the PPI.[@B11],[@B12] The aims of this study were to obtain base-line data on the extent of reading PPIs by consumers and possible factors that might affect this, to explore the attitude of the Palestinian public and healthcare professionals towards the patient package inserts, and to review a random sample of PPIs for the availability of different information. Results of this study provide information for healthcare providers and educators. Improvements in self-education about medications may be related to appropriate use of medications and improve people's ability to care for medical problems.

Methods
=======

The first part of the study was a cross-sectional self-administered questionnaire. It was conducted between March and May 2010. The questionnaires were developed based on review of literature and intended to assess the general attitude of patients and healthcare professionals (physicians and pharmacists) towards PPIs, their comprehensibility, and the information that they need to find in the PPIs. The questionnaire for consumers included 15 items: the first part included information regarding patient demographics and clinical characteristics including: sex, age, education, place of living, insurance, evaluation of health status in general, and presence of chronic diseases. The consumers were asked if they read the PPI and check the expiry date before using medication, if they find the font size suitable, what is the language that they prefer to read the PPIs in, if they find the information in the PPIs clear and enough, if they think that the PPIs in our country need improvement and if they think that a free number in the PPIs to give any required drug information can be useful. Finally, they were given a list of PPIs sections and were asked what parts they find important and useful to them. The questionnaire for healthcare professionals included 10 items and it was very similar to that of consumers with some modifications. Professionals were asked about their sex, age, specialty and years of experience. They were asked if they find the font size suitable, what is the language that they prefer to read the PPIs in, if they find the information in the PPIs clear and enough, if they think that the PPIs in our country need improvement and if they think that a free number in the PPIs to give any required drug information can be useful. They were given a list of PPIs sections and were asked what parts they find important and useful to them. The professionals\' list included pharmacokinetics data, consumers were not asked about this section because it might be difficult for them to understand this. The questionnaires were in Arabic, the last question that included sections of the PPIs was in both Arabic and English. Preliminary test of the questionnaires was conducted on 20 persons for each and slightly modified according to this. After having the approval from the Institutional Review Board at An-Najah National University, the questionnaires were distributed randomly by 30 fourth year pharmacy students. They were asked to choose consumers and healthcare professionals from their living areas. The students are from various cities and villages in the West Bank, so a convenient sample from randomly selected places was obtained. In the second part of the study, a random sample of 135 PPIs was reviewed. In our community pharmacies, the medications are arranged according to their producing company, a researcher was asked to choose randomly 10-15 medications for every company to check for the availability of pharmacological, pharmaceutical and clinical information as active ingredient, adverse drug reactions, warnings and precautions, clinical indication, contraindication, drug-drug interaction, direction for use, storage condition, overdose toxicity, dosages, pregnancy implications, lactation implications, list of excipients (inactive ingredients), and expiry after opening or reconstitution. The data were entered and descriptively analyzed using the Statistical Package for the Social Sciences (SPSS) software program version 16.0. Associations between categorical variables and reading PPIs were assessed using the chi-square test.

Results
=======

A total of 304 healthcare professionals and 223 consumers answered the survey. The healthcare professionals were 146 physicians and 158 pharmacists. Only 16 physicians and pharmacists refused to fill the questionnaire giving a response rate of 95%. Out of 240 consumers, 223 accepted to participate giving a response rate of 92.9%. The consumers\' sample consisted of 37.6% males and 62.4% females. The distribution of their ages was: 16--26 (28.1%), 26-39 (21.9%), 40-59 (44.8%), and 60 or older (4.0%).

Among the 222 consumers who answered the question regarding the reading of the PPIs, 100 patients (45.0%) reported that they always read the information in the leaflet of the drug package, 65 (29.3%) said that they read the PPIs most of the times, 41 (18.5%) said that read it sometimes, and only 16 (7.2%) participants said that they rarely or do not read the PPIs.

Consumers\' age, education, place of living, health status in general, and presence of chronic diseases were not associated with reading the PPIs, but gender was. Increased rate of reading the PPIs was found among females (P=0.047). Of the 223 consumers who answered the questionnaire, 183 (82.1%) said that they read the expiry date of the medications before using them, 10 (4.5%) said that they do not read it and 30 (13.5%) said that they read the expiry date sometimes.

The consumers and the healthcare professionals were asked if they find the font size in the PPIs suitable for reading or not? 35.9% of the consumers and 43.6% of the healthcare professionals answered with yes, 28.7% of the consumers and 18.5% of the healthcare professionals answered with no, and third group of 35.4% consumers and 38.0% healthcare professionals said that they find font size suitable sometimes and very small other times.

Among the consumers who read the PPIs, 94 (42.3%) said that they found the information in the PPIs useful and enough, while 32 (14.4%) found the PPIs to be vague, un-useful and that they could not find the needed information readily. A third group, 96 (43.2%) said that they sometimes find the PPIs useful and enough, and sometimes not. Less healthcare professionals 77 (25.5%) found the information in the PPIs enough, 111 (36.8%) of them thought it was not enough, and 114 (37.7%) said it is sometimes enough.

The attitudes of consumers and healthcare professionals towards the importance of different information sections of the patient package inserts are shown in [Table 1](#T1){ref-type="table"}. They both told that they find most sections of the PPIs important and useful to them.

###### 

Attitude of consumers and healthcare professionals towards the importance of different information sections of the patient package inserts

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Section Importance                                                                                                                                  Consumers N (%)\   Healthcare Professionals N (%)\                
                                                                                                                                                      N = 223            N = 304                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ --------------------------------- ------------ ------------
  Active ingredient                                                                                                                                   150 (67.3)         73 (32.7)                         279 (92.4)   23 (7.6)

  Clinical indication                                                                                                                                 220 (98.7)         3 (1.3)                           223 (73.4)   81 (26.6)

  Contraindication                                                                                                                                    211 (94.6)         12 (5.4)                          295 (97.0)   9 (3.0)

  Pregnancy implications                                                                                                                              184 (83.3)         37 (16.7)                         300 (98.7)   4 (1.3)

  Lactation implications                                                                                                                              182 (82.0)         40 (18)                           300 (98.7)   4 (1.3)

  Warnings and precautions                                                                                                                            221 (99.1)         2 (0.9)                           298 (98.0)   6 (2.0)

  Drug-Drug interaction                                                                                                                               201 (90.5)         21 (9.5)                          292 (96.4)   11 (3.6)

  Drug-food interactions                                                                                                                              198 (88.8)         25 (11.2)                         285 (94.1)   18 (5.9)

  Adverse drug reactions                                                                                                                              217 (97.3)         6 (2.7)                           293 (96.4)   11 (3.6)

  Dosages                                                                                                                                             196 (87.9)         27 (12.1)                         277 (91.4)   26 (8.6)

  Direction for use                                                                                                                                   207 (93.2)         15 (6.8)                          290 (95.4)   14 (4.6)

  Overdose toxicity                                                                                                                                   203 (91.0)         20 (9.0)                          285 (93.8)   19 (6.2)

  Storage condition                                                                                                                                   180 (80.7)         43 (19.3)                         275 (90.8)   28 (9.2)

  Expiry after opening or reconstitution                                                                                                              218 (97.8)         5 (2.2)                           296 (97.4)   8 (2.6)

  List of excipients (inactive ingredients)                                                                                                           40 (19.0)          171 (81.0)                        100 (32.9)   204 (67.1)

  Storage conditions after opening or reconstitution of the drug                                                                                      194 (92.8)         15 (7.2)                          291 (95.7)   13 (4.3)

  Possibility of tablet splitting                                                                                                                     173 (82.0)         38 (18.0)                         246 (81.2)   57 (18.8)

  Possibility of crushing tablets or opening capsules to mix with food or beverages                                                                   167 (79.1)         44 (20.9)                         249 (82.2)   54 (17.8)

  Instructions to convert tablets or capsules into liquid dosage forms when they are not available                                                    158 (74.9)         53 (25.1)                         232 (76.3)   72 (23.7)

  Pharmacokinetics information                                                                                                                        NA                 NA                                134 (44.2)   169 (55.8)

  Note: the total number of consumers and healthcare professionals might not be 223 or 304 as some participants might miss to answer some questions                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

When the participants were asked if they think that the information in the PPIs need to be improved, 167 (74.0%) of the consumers and 252 (83.7%) of the healthcare professionals answered with yes. 212 (95.1%) the consumers and 255 (84.7%) of the healthcare professionals thought that a free telephone number in the PPIs would be a good idea to provide drug information when needed.

The PPIs of 135 medications were reviewed for the availability of pharmacological and pharmaceutical information. Some sections were available in most of the PPIs reviewed (\>90%). Those sections were: active ingredient, adverse drug reactions, warnings and precautions, clinical indication, contraindication, drug-drug interaction, and direction for use. Other sections as storage condition, overdose toxicity, dosages, pregnancy implications, lactation implications, list of excipients (inactive ingredients), and expiry after opening or reconstitution were available in some PPIs with rates ranging from 86.7% to 47.4%. For the rest of the sections, they were not included in most of the PPIs ([Table 2](#T2){ref-type="table"}).

###### 

The availability of information in a sample of patient package inserts

  --------------------------------------------------------------------------------
  Information                                                      Total N (%)\
                                                                   N = 135
  ---------------------------------------------------------------- ---------------
  Active ingredient                                                135 (100.0)

  Adverse drug reactions                                           134 (99.3)

  Warnings and precautions                                         133 (98.5)

  Clinical indication                                              131 (97.0)

  Contraindication                                                 129 (95.6)

  Drug-Drug interaction                                            127 (94.1)

  Direction for use                                                126 (93.3)

  Storage condition                                                117 (86.7)

  Overdosage toxicity                                              96 (71.1)

  Dosages                                                          94 (69.6)

  Pregnancy implications                                           92 (68.2)

  Lactation implications                                           86 (63.7)

  List of excipients (inactive ingredients)                        65 (48.2)

  Expiry after opening or reconstitution                           64 (47.4)

  Pharmacokinetics information                                     11(8.2)

  Drug-food interactions                                           27/106 (25.5)

  Storage conditions after opening or reconstitution of the drug   16/47 (34.0)

  Possibility of tablet splitting                                  16/47 (34.0)

  Possibility of crushing and mixing with food or beverages        8/47 (17.0)

  Instructions to convert tablets or capsules into liquid forms    0/47 (0.0)
  --------------------------------------------------------------------------------

Discussion
==========

The PPI has to reinforce or even supplement professional explanations. Written information which is available to the patient at home can help to bridge the communication gap between patient and physician reinforcing the warnings, instructions and explanations given to the patient by both doctor and pharmacist. Rates of reading the package insert vary. In our study, 45.0% reported that they always read the information in the PPIs, 29.3% said that they read them most of the times. Compared to other countries, a study from the United States has shown that for leaflets provided with new medications, 49.2%, 21.2%, 16.0%, and 13.7% of surveyed patients reported reading the leaflets always, often, seldom, or never, respectively.[@B13] In Turkey, 78.2% patients reported that they read the leaflets.[@B14] A survey performed in Italy showed that most of the patients (83.4%) read the PPIs.3 Horwitz *et al*,[@B15] found that 79% always or often read the patient information leaflets. In a survey from the United Kingdom, 47% patients said that they read some of the patient information leaflet, and. 35% said that the read it all.[@B16] These results show that a high percentage of our consumers read the PPIs before using the medications, but still the importance of this needs to be confirmed. Health professionals, particularly pharmacists, are well placed to raise awareness of this. Pharmacists should advocate reading the leaflet and promote it as a useful resource of drug information. In this study, it was found that the gender was the only demographic variable associated with reading the leaflet. Koo *et al*,[@B17] investigated patients' use of written medicine information in Australia, they have found that the level of patient health literacy, health locus of control, occupation, patient coping style and the nature of the health problem were all associated with patient interest in written materials. Another study has shown that literacy was positively associated with reading of written medicine information, while age was negatively associated with reading them.[@B18]

In this study, 28.7% of the consumers and 18.5% of the healthcare professionals said that they do not find the font size in the PPIs suitable for reading, and 35.4% consumers and 38.0% healthcare professionals said that they find font size suitable sometimes and very small other times. In a study by Bernardini *et al*,[@B4] a great majority of the respondents (63.1%) said that the print size is too small. This percentage rose with increasing age. From their survey it emerged that people would prefer 10 and 11 points. In Horwitz *et al*.[@B15] study, 38% of the interviewed patients had problems reading or understanding the patient information leaflets. Older consumers may be unable to acquire information in the \'fine\' print frequently found in various kinds of product inserts.[@B19] It is recommended that a suitable size should be chosen. PPI inserted in medicines for geriatric pathologies should be written in at least 10 points Didot. Recently, the Pharmaceutical Committee of the European Commission has also taken into consideration the formal aspects of the PPIs and has formulated a guideline on the readability of the label and PPIs of medicinal products for human use.[@B4] According to such a guideline, the information appearing in the leaflet should be printed in characters of at least 8 points Didot and one or several colors may be used for printing characters because the use of different colors is one way of making headings clearly recognizable. Capitals letters should not be used indiscriminately because they detract from the readability, but they may be useful for emphasis. As we do not have our own guidelines, our MoH could benefit from these guidelines to improve the readability of the PPIs in our market.

Among the consumers who read the PPIs, 42.3% said that they found the information in the PPIs useful and enough and less healthcare professionals 25.5% found the information in the PPIs enough. Inadequate information in the PPIs has been reported by authors in different countries. In a study carried out in Saudi Arabia, the authors found that there was substantial disagreement in information between generic package inserts and the British National Formulary and the package inserts of the brand products marketed in Saudi Arabia.[@B6] In the USA, it was shown that PPIs do not fully meet the federal regulations.[@B20] A European study found substantial disagreement in the materials available to prescribers and patients in different countries.[@B21] A study in our country found that there is a significant difference in the quantity and quality of information provided in the PPIs of locally and imported anti-infective agents.[@B12] Another study has found that instructions for storage and proper use were not available in package inserts of many oral drops products in Palestine.[@B22] PPIs improvement will better direct health practices to the benefit of the patients. In Bernardini *et al*.[@B4] study, the great majority of respondents (60.6%) preferred a more detailed leaflet. Regarding the subgroups, the percentage increased with decreasing levels of study. Most of the population (61.1%) said that they would prefer a more schematic and concise leaflet. It is apparent that our patients and healthcare professionals would appreciate a more detailed PPI, but information should be given in schematic and concise way. This requires the MoH to develop clear regulations regarding the content of the PPIs.

Consumers and healthcare professionals find most sections of the PPIs important and useful. Despite the importance of these sections, a review of a sample of PPIs has shown that many PPIs in our market miss some sections or include unclear and unspecific information. A study from USA to evaluate the distribution and quality of patient medication leaflets provided in U.S. pharmacies has found that fewer than 10% of all leaflets met quality criteria regarding contraindications, precautions, and how to avoid harm. One fourth of all leaflets had poor print size, according to the shoppers.[@B20] Another study to evaluate the quality of patient information leaflets provided with dispensed medications in the United States, United Kingdom, and Australia has found that the U.S. leaflets achieved ≤50% adherence for contraindication and precaution information. Omissions included warnings about preexisting allergy and illness and information about drug interactions. The U.S. leaflets also scored poorly (60%) for legibility and comprehensibility. The U.K. score reflected shortcomings in information about how to use and monitor the medications and on adverse drug reactions.[@B8] In Germany, a study of 68 German package inserts for a detailed analysis of their quality and suitability has found that in many cases package inserts did not include important information or were difficult to read or understand.[@B23] It seems that this problem is seen in both developed and developing countries, as it was recommended before suitable regulations from our MoH can control this problem.

In general, 74.0% of the consumers and 83.7% of the healthcare professionals said that the information in the PPIs needs to be improved. It is clear that actions should be done to improve the pharmacological and the pharmaceutical contents in our PPIs. This requires regulations from related authorities and cooperation from pharmaceutical companies. There is definitely a need to update the guidelines for package inserts in line with those from the Western countries. Improvements such as adoption of a uniform format and implementation of guidelines regarding inclusion of relevant information could greatly enhance the quality and clarity, and satisfy the people needs.

A suggested solution that could be helpful if the PPIs cannot be modified to include all the required information is to include a free telephone number in the PPIs to provide extra drug information when needed. This idea was welcomed by 95.1% the consumers and 84.7% of the healthcare professionals. At our institution, we have a poison control and drug information center that provides drug related information freely. The free telephone number of this center can be added to the PPIs.

Our results should, however, be considered in the context of some limitations. Samples of consumers, healthcare professionals and medications for reviewing PPIs were collected randomly to have convenient samples. As they were collected by many pharmacy students, this raises the possibility of selection bias and might not be generalized to the general population. However, these results can give base-line data about the situation in our country which meets with the aims of this study. Also no measures were put in place to ascertain the claim made by participants about reading the PPIs, we just recorded what they said, further studies could assess this point.

Conclusions
===========

A high percentage of the consumers read the PPI before using the medications, but still the importance of this needs to be confirmed by pharmacists. Palestinian authorities and manufacturers should implement appropriate measures to regulate the quality and quantity of information in the patient package insert. PPIs improvement will better direct health practices to the benefit of the patients. Package inserts readability and content must be optimized. This will avoid misunderstandings and lack of information and ensure that use of the drug will give the best possible outcome and avoid safety risks. It is recommended that pharmacists should advocate reading the PPI and promote it as a useful resource of drug information, but they need to provide consumers with detailed counseling to compensate for the missing information in some of the PPIs. a suitable font size should be used in the PPIs to encourage people to read it easily, PPIs should be more detailed but the information should be given in a schematic and concise way, and PPIs should contain pharmaceutical information about the appropriate use of dosage forms.
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